Lack of interleukin‐2 (IL‐2) expression and selective expression of IL‐10 mRNA in human renal cell carcinoma
暂无分享,去创建一个
E. Halapi | R. Kiessling | C. Juhlin | P. Pisa | H. Nakagomi | K. Backlin | E. Pisa | Yasuyoshi Yamamoto | Y. Yamamoto
[1] M. Matsuda,et al. IL-10 converts mouse lymphoma cells to a CTL-resistant, NK-sensitive phenotype with low but peptide-inducible MHC class I expression. , 1995, Journal of immunology.
[2] M. Matsuda,et al. Interleukin 10 pretreatment protects target cells from tumor- and allo- specific cytotoxic T cells and downregulates HLA class I expression , 1994, The Journal of experimental medicine.
[3] D. Longo,et al. Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. , 1993, Cancer research.
[4] M. Matsuda,et al. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. , 1993, Cancer research.
[5] M. Chen,et al. Interleukin‐10 production by human carcinoma cell lines and its relationship to interleukin‐6 expression , 1993, International journal of cancer.
[6] Mohamed,et al. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. , 1993, The Journal of clinical investigation.
[7] G. Tosato,et al. Human interleukin-10 can directly inhibit T-cell growth. , 1993, Blood.
[8] M. de Carli,et al. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. , 1993, Journal of immunology.
[9] D. Longo,et al. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. , 1992, Science.
[10] J. Berek,et al. Presence of interleukin 10 (IL-10) in the ascites of patients with ovarian and other intra-abdominal cancers. , 1992, Cytokine.
[11] E. Halapi,et al. Selective expression of interleukin 10, interferon gamma, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[12] T. Whiteside,et al. Expression of mRNA for cytokines in tumor‐infiltrating mononuclear cells in ovarian adenocarcinoma and invasive breast cancer , 1992, International journal of cancer.
[13] H. Spits,et al. Differential effects of IL-4 and IL-10 on IL-2-induced IFN-gamma synthesis and lymphokine-activated killer activity. , 1992, International immunology.
[14] A. Sher,et al. IL-10 inhibits parasite killing and nitrogen oxide production by IFN-gamma-activated macrophages. , 1992, Journal of immunology.
[15] M. Howard,et al. Ly‐1 B (B‐1) cells are the main source of B cell‐derived interleukin 10 , 1992, European journal of immunology.
[16] U. Reinhold,et al. Tumor‐infiltrating lymphocytes isolated from a Ki‐1–positive large cell lymphoma of the skin. Phenotypic characterization and analysis of cytokine secretion , 1991, Cancer.
[17] J. Convit,et al. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. , 1991, Science.
[18] C. Figdor,et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression , 1991, The Journal of experimental medicine.
[19] N. Chakraborty,et al. Suppression of lymphokine-activated killer cell generation by tumor-infiltrating lymphocytes. , 1991, Clinical immunology and immunopathology.
[20] T. Mosmann,et al. The role of IL-10 in crossregulation of TH1 and TH2 responses. , 1991, Immunology today.
[21] S. Miescher,et al. Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors. , 1987, Journal of immunology.
[22] P. Chomczyński,et al. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.
[23] A. Chang,et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. , 1985, The New England journal of medicine.
[24] J. Svennevig,et al. Lymphoid infiltration and prognosis in colorectal carcinoma. , 1984, British Journal of Cancer.
[25] S. Poppema,et al. Insitu analysis of the mononuclear cell infiltrate in primary malignant-melanoma of the skin , 1983 .